{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:56:15Z","timestamp":1756572975113},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T00:00:00Z","timestamp":1244419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2009,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cyclin\u2010A2, a key cell cycle regulator, has been shown to be overexpressed in various types of malignancies with little expression in normal tissue. Such tumor\u2010associated genes potentially are useful targets for cancer immunotherapy. However, high\u2010avidity cyclin\u2010specific T cells are considered to be thymically deleted. We identified at least one nonameric HLA\u2010A*0201 binding cyclin\u2010A2 epitope by a reverse immunology approach. Using a highly efficient T\u2010cell expansion system that is based on CD40\u2010activated B (CD40\u2010B) cells as sole antigen\u2010presenting cells we successfully generated cyclin\u2010A2 specific CTL from HLA\u2010A*0201<jats:sup>+<\/jats:sup> donors. Interestingly, high\u2010avidity cyclin\u2010A2 specific CTL lines, which recognized peptide\u2010pulsed and antigen expressing target cells, were indeed generated by stimulation with CD40\u2010B cells when pulsed with low concentrations of peptide, whereas CD40\u2010B cells pulsed at saturating concentrations could only induce low\u2010avidity CTL, which recognized peptide\u2010pulsed target cells only. One high\u2010avidity CTL line was subcloned and CTL clones, whose peptide concentration required for half\u2010maximal lysis were less than 1 nM, could lyse cyclin\u2010A2 expressing tumor cells. Taken together, cyclin A2 is an attractive candidate for immune intervention in a significant number of cancer patients and high\u2010avidity T cells can be readily generated using CD40\u2010B cells as antigen\u2010presenting cells. \u00a9 2009 UICC<\/jats:p>","DOI":"10.1002\/ijc.24629","type":"journal-article","created":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T15:38:57Z","timestamp":1244475537000},"page":"2474-2478","source":"Crossref","is-referenced-by-count":8,"title":["The shared tumor associated antigen cyclin\u2010A2 is recognized by high\u2010avidity T\u2010cells"],"prefix":"10.1002","volume":"125","author":[{"given":"Eisei","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Maecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Draube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nela","family":"Klein\u2010Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Shimabukuro\u2010Vornhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim L.","family":"Schultze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"von Bergwelt\u2010Baildon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90028-W"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3389"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1351"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7652577"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4049\/jimmunol.157.1.239","article-title":"A synthetic peptide derived from the tumor\u2010associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein","volume":"157","author":"Dahl AM","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-002-8510-y"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.3.5.617"},{"key":"e_1_2_5_9_2","first-page":"235","article-title":"Cyclin A expression in human hematological malignancies: a new marker of cell proliferation","volume":"53","author":"Paterlini P","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600072"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65638-6"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3319"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.4.2164"},{"key":"e_1_2_5_15_2","first-page":"2836","article-title":"CD40\u2010stimulated B lymphocytes pulsed with tumor antigens are effective antigen\u2010presenting cells that can generate specific T cells","volume":"63","author":"Lapointe R","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_16_2","first-page":"2836","article-title":"CD40\u2010stimulated B lymphocytes pulsed with tumor antigens are effective antigen\u2010presenting cells that can generate specific T cells","volume":"63","author":"von Bergwelt\u2010Baildon M","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_16_3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3606"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152041"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001464"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1374"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20906"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115601"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.1.163"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002510050595"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg510"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btg247"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0825"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(94)90283-6"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00265-5"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.2.989"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.162.4.2227","article-title":"Isolation of high avidity melanoma\u2010reactive CTL from heterogeneous populations using peptide\u2010MHC tetramers","volume":"162","author":"Yee C","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22957"},{"key":"e_1_2_5_32_2","first-page":"5818","article-title":"Integrated functional genomics approach for the design of patient\u2010individual antitumor vaccines","volume":"62","author":"Weinschenk T","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<193::AID-IMMU193>3.0.CO;2-K"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.121540098"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M203951200"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208795"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.9.1313"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.24629","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.24629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:52:58Z","timestamp":1695941578000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.24629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,18]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,11,15]]}},"alternative-id":["10.1002\/ijc.24629"],"URL":"https:\/\/doi.org\/10.1002\/ijc.24629","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,18]]}}}